Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

EP: 1.Overview of Low-Risk MDS: Clinical Hallmarks and Current Treatments

EP: 2.Incorporating Prognostic Scoring Systems in Treatment Decisions for Lower-Risk MDS

EP: 3.The Role of Luspatercept as First-Line Treatment in Lower-Risk MDS

EP: 4.Impact of Improved Hemoglobin Levels on Patient Well-being and Quality of Life

EP: 5.Approaches to Initiating and Adjusting Luspatercept Dosing

Now Viewing

EP: 6.Comparing Treatment Options: Luspatercept vs. Erythropoiesis-Stimulating Agents (ESAs)

EP: 7.Advancing the Treatment Landscape for Lower-Risk MDS: Unmet Needs and Future Directions

EP: 8.Transitioning to Alternative Therapies: Topoisomerase Inhibitors vs. Hypomethylating Agents

Video content above is prompted by the following question(s):

• When it comes to initial anemia treatment beyond transfusions, there are different options available including luspatercept and erythropoiesis-stimulating agents (ESAs).
  • What factors would you consider when deciding between these therapies for a particular patient?
• For patients already on ESAs, what would prompt you to consider transitioning them to luspatercept therapy?
• How do you determine the appropriate timing for such a switch?
• Please discuss the clinical benefit of luspatercept dose titration from the RWE data presented at EHA 2024.